AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) CEO Thomas K. Equels will appear in a live, moderated "fireside" chat on the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. The discussion will focus on AIM's clinical and regulatory strategy for lead drug Ampligen, including the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer.
Equels will also review a completed Phase 2 trial with Merck evaluating Ampligen plus Keytruda (pembrolizumab) in advanced recurrent ovarian cancer; an abstract was presented at the 40th Annual SITC Meeting. Interested parties can submit questions in advance to aim@jtcir.com. A live webcast will stream on the company's Events page and a replay will be available two hours after the live presentation for 90 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AIM
On the day this news was published, AIM gained 1.98%, reflecting a mild positive market reaction. Argus tracked a trough of -13.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $89K to the company's valuation, bringing the market cap to $4.57M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | CEO video update | Positive | -2.7% | CEO Corner segment on pancreatic cancer unmet need and Ampligen program. |
| Dec 01 | Investor event notice | Positive | +2.0% | Announcement of fireside chat on Ampligen strategy and DURIPANC trial. |
| Nov 18 | Earnings and pipeline | Neutral | -7.6% | Q3 2025 results with limited cash and continued Ampligen pipeline focus. |
| Nov 10 | Clinical data update | Positive | -6.4% | Detailed Phase 2 ovarian data showing 50% ORR with Ampligen combo. |
| Nov 04 | Conference abstract | Positive | -20.4% | Late-breaking SITC abstract acceptance for Ampligen ovarian cancer study. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent sell-offs after clinically positive or visibility-enhancing news, with several declines following favorable Ampligen updates and conference-related announcements.
This announcement continues AIM’s recent focus on visibility and Ampligen’s oncology program. In November 2025, the company highlighted DURIPANC trial progress and ovarian cancer data, including a 50% ORR in a Phase 2 study. Third-quarter 2025 results showed limited cash of $2.4M and a net loss of $(3.3M), underscoring financing needs. A prior, nearly identical fireside-chat announcement on Dec 1, 2025 saw a modest +1.97% move, while other positive clinical headlines often coincided with price declines.
Key Terms
clinical trial medical
immune checkpoint inhibitor medical
metastatic pancreatic cancer medical
Phase 2 clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET
OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET.
As part of the event, Equels will participate in a moderated “fireside” chat that will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer. Equels will also discuss the importance of a completed Phase 2 clinical trial performed in collaboration with Merck Sharp & Dohme LLC (“Merck”), which found that the combination therapy of Ampligen and Merck’s Keytruda (pembrolizumab) was well-tolerated and demonstrated clinical benefit in the treatment of advanced recurrent ovarian cancer. An abstract detailing the trial was recently presented at the 40th Annual SITC Meeting.
Prior to the event, interested parties may submit questions in advance by emailing aim@jtcir.com. Equels will answer as many questions as possible in the time allowed.
A live video webcast of the fireside chat will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com